Clinical trials
Refractory Lymphoma clinical trials
Below are recruiting refractory lymphoma clinical trials, each written for real people, not researchers. We’re tracking 304 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06703892RecruitingPhase 1
CAR T-cell therapy for relapsed B-cell lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
TaipeiAges 18–70 - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06784726RecruitingPhase 2
Odronextamab before CAR-T for large B-cell lymphoma
This trial tests a drug called odronextamab for people with large B-cell lymphoma whose cancer did not respond to or came back after initial treatment. The goal is to see if odronextamab can help shrink the tumor before getting CAR-T cell therapy.
Seattle, WashingtonAges 18 years+ - NCT06834373RecruitingPhase 2
Golcadomide and rituximab before CAR T for lymphoma
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06839053RecruitingPhase 2
Study of sonrotoclax, rituximab, and zanubrutinib for CLL, SLL, and MCL
This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.
Seattle, WashingtonAges 18 years+ - NCT06854159RecruitingPhase 2
Odronextamab for diffuse large B-cell lymphoma before and after CAR T therapy
This trial tests a drug called odronextamab for people with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. It aims to see if the drug can help before and after a type of immunotherapy called CAR T-cell therapy.
Sacramento, CaliforniaAges 18 years+ - NCT06859008RecruitingPhase 1
Zanubrutinib and sonrotoclax for B-cell lymphoma in diverse groups
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
Duarte, CaliforniaAges 18 years+ - NCT07042438RecruitingPhase 2
Fecal transplant to improve CAR T therapy for lymphoma
This study tests whether a fecal transplant (transferring healthy gut bacteria) can improve outcomes for people with certain lymphomas who have taken strong antibiotics and are about to get CAR T-cell therapy (Yescarta). The goal is to see if rebuilding gut bacteria helps the treatment work better.
Duarte, CaliforniaAges 18 years+ - NCT07098364RecruitingPhase 1/Phase 2
ST-067 with CAR T-cell therapy for large B-cell lymphoma
This trial tests a new drug, ST-067, combined with a CAR T-cell therapy (liso-cel) for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if the combination is safe and effective.
Seattle, WashingtonAges 18 years+ - NCT07365306RecruitingPhase 2
Epcoritamab with chemo before stem cell transplant for DLBCL
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Duarte, CaliforniaAges 18 years+ - NCT06905509RecruitingPhase 2
Epcoritamab with chemo and stem cell transplant for large B-cell lymphoma
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
Sacramento, CaliforniaAges 18 years+ - NCT04587687RecruitingPhase 2
Brentuximab plus bendamustine for relapsed follicular lymphoma
This Phase 2 trial studies the combination of brentuximab vedotin and bendamustine in people whose follicular lymphoma has come back or did not respond. It aims to shrink the lymphoma and improve outcomes after at least one prior treatment.
Sacramento, CaliforniaAges 18 years+ - NCT07502768RecruitingPhase 1/Phase 2
Tislelizumab and Zeprumetostat for Lymphoma
This trial tests a combination of two drugs (tislelizumab and zeprumetostat) for people whose NK/T-cell lymphoma has returned or stopped responding to previous treatment. The goal is to see if the combination works better than what has been tried before.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05755087RecruitingPhase 1
Tegavivint for relapsed or hard-to-treat lymphoma patients
This Phase 1 trial tests tegavivint, a new investigational medicine, for certain types of aggressive B-cell lymphoma that have come back or did not respond to prior treatment. It may help shrink the lymphoma and learn how safe and effective the drug is in this setting.
Columbus, OhioAges 18 years+ - NCT04871607RecruitingPhase 2
Yttrium antibody plus chemotherapy for hard-to-treat Hodgkin lymphoma
This trial studies a targeted antibody therapy with yttrium, combined with intensive chemotherapy, for adults whose Hodgkin lymphoma did not respond well or came back. It may help by delivering cancer-killing radiation directly to lymphoma cells and preparing the body for treatment after transplant conditioning.
Duarte, CaliforniaAges 18 years+ - NCT05963217RecruitingPhase 1
Study of a patient’s own CAR T cells for CD19 cancers
This Phase 1 study tests a personalized form of CAR T cell treatment made from your own immune cells to fight certain CD19-positive blood cancers that have returned or not responded to prior treatment. It mainly looks at safety and how well the treatment can work.
Toronto, OntarioAges 18 years+ - NCT06916767RecruitingPhase 1
Study of BAFF CAR-T cells for CLL or SLL
This trial tests a new type of immune cell therapy (BAFF CAR-T cells) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded after at least two prior treatments, including a BTK inhibitor and a BCL2 inhibitor. The goal is to see if these engineered cells can fight the cancer.
Cleveland, OhioAges 18 years+ - NCT06675123RecruitingPhase 1
Pacritinib with a BTK inhibitor for mantle cell lymphoma
This trial tests a new combination of two targeted drugs (pacritinib plus a BTK inhibitor like ibrutinib) for people with mantle cell lymphoma that has come back or stopped responding to treatment. It may help if your current BTK inhibitor is no longer working well.
Duarte, CaliforniaAges 18 years+ - NCT04484012RecruitingPhase 2
CAR T cells plus acalabrutinib for mantle cell lymphoma
This trial tests whether modified immune cells (CD19 CAR T cells) given with the medicine acalabrutinib can help people with mantle cell lymphoma that has come back or did not respond. It may help by attacking lymphoma cells more strongly and improving disease control after prior treatment.
Duarte, CaliforniaAges 18–75 - NCT04989621RecruitingPhase 2
Orelabrutinib plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether orelabrutinib combined with rituximab, followed by orelabrutinib alone for a while, can control follicular lymphoma that has come back or did not respond. It may help shrink tumors and keep the disease from worsening after initial response.
Guangzhou, GuangdongAges 18 years+ - NCT05910801RecruitingPhase 2
Tafasitamab plus lenalidomide and venetoclax for relapsed lymphoma
This Phase 2 trial studies tafasitamab together with lenalidomide and venetoclax in people with mantle cell lymphoma (MCL) that has come back or did not respond to prior treatment. It may help shrink the lymphoma and improve disease control when standard options have not worked.
Rochester, MinnesotaAges 18 years+ - NCT06826118RecruitingPhase 2
Car t-cell therapy for relapsed follicular lymphoma
This trial tests a new car t-cell treatment (axicabtagene ciloleucel) for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if this therapy can help control the lymphoma.
Xiamen, FujianAges 18 years+ - NCT04545762RecruitingPhase 1
Anti-CD19 CAR-T for certain relapsed lymphoma
This Phase 1 study tests an anti-CD19 CAR-T cell treatment in adults with specific types of relapsed or treatment-resistant non-Hodgkin lymphoma. It may help by finding and attacking lymphoma cells that carry the CD19 marker, but it’s early-stage and eligibility is strict.
San Francisco, CaliforniaAges 18 years+ - NCT06386315RecruitingPhase 2
Lower dose radiation for slow-growing lymphoma
This trial tests whether giving a lower dose of radiation than usual works well for people with slow-growing B-cell lymphomas. It aims to reduce side effects while still controlling the disease.
Scottsdale, ArizonaAges 18 years+
Hear when a new Refractory Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory lymphoma?
- Yes. Clin2 currently lists 304 recruiting refractory lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.